XLO

+ Watchlist + Portfolio

Xilio Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.82
52-Week Range: $6.47 – $12.59
Market Cap: $59.29M
P/E (TTM): —
EPS (TTM): -0.32
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.16
PEG Ratio: —
Return on Equity: -55.03%
Return on Assets: -13.61%
Gross Margin: 83.16%
Operating Margin: -18.68%
Profit Margin: -34.06%
Current Ratio: 4.25
Debt/Equity: 0.09
Total Debt: $6.30M
Free Cash Flow: $-37.56M
Revenue Growth: 131.20%
Earnings Growth: —
Enterprise Value: $-70.45M

XLO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$6.34M	$43.77M
Research & Development	$59.20M	$52.14M	$41.21M	$56.04M
Selling, General & Admin	$29.95M	$27.00M	$24.78M	$29.71M
Operating Expenses	$89.15M	$79.13M	$65.99M	$85.75M
Operating Income	-$89.15M	-$79.13M	-$59.65M	-$41.98M
EBITDA	-$87.30M	-$77.23M	-$58.00M	-$40.44M
Pretax Income	-$88.22M	-$76.40M	-$58.24M	-$35.04M
Net Income	-$88.22M	-$76.40M	-$58.24M	-$35.04M
Diluted EPS	-45.08	-38.92	-15.26	-4.19
Diluted Shares	1.96M	1.96M	3.82M	8.36M

XLO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$120.39M	$44.70M	$55.29M	$137.53M
Receivables	—	—	$0.00	$5.00M
Current Assets	$124.50M	$48.13M	$60.23M	$145.03M
Total Assets	$139.16M	$60.93M	$71.08M	$154.69M
Current Liabilities	$21.12M	$15.96M	$27.26M	$56.27M
Long-Term Debt	$3.17M	—	—	—
Total Debt	$19.94M	$12.50M	$8.14M	$6.95M
Total Liabilities	$33.52M	$24.10M	$53.48M	$119.41M
Retained Earnings	-$249.11M	-$325.51M	-$383.75M	-$418.79M
Shareholders' Equity	$105.65M	$36.83M	$17.60M	$35.27M
Working Capital	$103.38M	$32.17M	$32.97M	$88.75M

XLO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$75.72M	-$68.62M	-$18.38M	-$4.99M
Capital Expenditure	-$1.87M	-$486.00K	-$36.00K	-$518.00K
Free Cash Flow	-$77.59M	-$69.11M	-$18.41M	-$5.51M
Depreciation & Amortisation	$1.85M	$1.90M	$1.64M	$1.54M
Stock-Based Compensation	$8.42M	$7.38M	$6.43M	$6.94M
Investing Cash Flow	-$1.87M	-$486.00K	-$36.00K	-$518.00K
Financing Cash Flow	-$69.00K	-$6.55M	$29.20M	$87.78M
Net Change in Cash	-$77.66M	-$75.66M	$10.78M	$82.27M

XLO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.93M	$8.08M	$19.07M	$13.69M	$12.65M	$18.69M
Research & Development	$8.27M	$15.33M	$14.32M	$18.12M	$19.83M	$14.56M
Selling, General & Admin	$8.52M	$7.12M	$6.67M	$7.40M	$6.93M	$7.62M
Operating Expenses	$16.78M	$22.45M	$21.00M	$25.52M	$26.76M	$22.18M
Operating Income	-$13.85M	-$14.37M	-$1.93M	-$11.84M	-$14.11M	-$3.49M
EBITDA	-$13.35M	-$13.98M	-$1.59M	-$11.51M	-$13.77M	-$3.16M
Pretax Income	-$13.27M	-$15.84M	-$16.29M	$10.36M	-$9.53M	-$6.37M
Net Income	-$13.27M	-$15.84M	-$16.29M	$10.36M	-$9.53M	-$6.37M
Diluted EPS	-2.49	-2.30	-1.54	0.81	-0.58	-0.33
Diluted Shares	3.70M	6.89M	10.29M	12.83M	5.78M	19.40M

XLO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$89.07M	$121.55M	$103.76M	$137.53M	$150.33M	$136.04M
Receivables	—	—	$17.50M	$5.00M	$0.00	$6.00M
Current Assets	$93.20M	$123.72M	$124.09M	$145.03M	$154.21M	$145.47M
Total Assets	$103.72M	$133.81M	$133.69M	$154.69M	$163.49M	$154.25M
Current Liabilities	$47.64M	$53.26M	$56.40M	$56.27M	$42.96M	$34.20M
Total Debt	$7.86M	$7.57M	$7.26M	$6.95M	$6.64M	$6.30M
Total Liabilities	$93.02M	$126.74M	$141.79M	$119.41M	$90.94M	$81.99M
Retained Earnings	-$397.02M	-$412.86M	-$429.15M	-$418.79M	-$428.32M	-$434.69M
Shareholders' Equity	$10.70M	$7.07M	-$8.10M	$35.27M	$72.54M	$72.26M
Working Capital	$45.56M	$70.46M	$67.69M	$88.75M	$111.25M	$111.27M

XLO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$28.98M	-$14.48M	-$17.50M	-$2.00M	-$22.34M	-$18.76M
Capital Expenditure	-$22.00K	-$401.00K	—	-$95.00K	-$556.00K	-$19.00K
Free Cash Flow	$28.96M	-$14.88M	-$17.50M	-$2.09M	-$22.90M	-$18.78M
Depreciation & Amortisation	$497.00K	$381.00K	$340.00K	$323.00K	$344.00K	$331.00K
Stock-Based Compensation	$1.53M	$1.35M	$1.12M	$2.93M	$2.21M	$1.60M
Investing Cash Flow	-$22.00K	-$401.00K	$0.00	-$95.00K	-$556.00K	-$19.00K
Financing Cash Flow	$4.83M	$47.36M	-$285.00K	$35.87M	$35.71M	$4.49M
Net Change in Cash	$33.79M	$32.48M	-$17.78M	$33.77M	$12.81M	-$14.29M

Market Snapshot

About

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies. The company utilizes its proprietary platform to engineer cytokines and other immune-modulatory proteins that are activated in the tumor microenvironment. Xilio aims to improve the therapeutic index of cancer treatments while reducing systemic toxicity.